EGFR and non-small cell lung carcinoma: Guidelines recommended first-line (1L) treatment of EGFR mutations advanced NSCLC with first- or second-generation (1G/2G) EGFR-tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib or afatinib (Lee et al., 2021).